High Quality API Powder Apixaban Intermediate CAS 27143-07-3

Model NO.
CAS 27143-07-3
Stock
2.00kg
Water
0.01%
Capacity
2500kg
Annul Sales
2000kg
Volume
200kg
Experience
10years
Ever Exported?
Yes
Market
India
Heavy Metal
10ppm
Application
for Antibacteria
Residual Solvent
Ethanol
Impurity
0.01%
Other Name
(Arry-470)
Sample
Free
Intermediate
Apixaban-2
Transport Package
Air
Specification
JP
Trademark
jianfeng
Origin
Shandong
HS Code
2939000000
Reference Price
$ 4.68 - 27.00
Contact Us

Product Description

 
Factory supply Best quality Apixaban Intermediate 27143-07-3 545445-44-1 bulk order
Product Description

 

CAS: 503612-47-3

MF: C25H25N5O4

MW: 459.5

Other name: BMS-562247-01

Description: Apixaban powder cas 503612-47-3 is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation. Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It is used as an alternative to wa11rfarin and does not require monitoring by blood tests.

High Quality API Powder Apixaban Intermediate CAS 27143-07-3
High Quality API Powder Apixaban Intermediate CAS 27143-07-3

 

Product Parameters
 

Test items

Standard

Results

Appearance

White to off-white powder

Conform

Melting Point

145-149ºC

145~148ºC

HPLC Assay

≥99.0%

>99.72%

LC/MS

Conformity with the structure

Conform

NMR

Conformity with the structure

Conform

Related substance

Total impurities≤1.0%

<1.0%

Any impurity≤0.1%<0.1%

Loss of drying

≤0.5%

0.3%


Our company sells more than 5 tons of Apixaban Intermediate to domestic export trading companies every year.
In recent years, we have started to do foreign market. Please contact me to obtain the factory price.
1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester503614-91-3Apixaban intermediate
Acetic acid, 2-chloro-2-[2-(4-methoxyphenyl)hydrazinylidene], ethyl ester27143-07-3Apixaban intermediate
2(1H)-pyridine,3-chloro-5,6-dihydro-1-(4-nitrophenyl)536760-29-9Apixaban intermediate
3-Morpholin-4-yl-1-[4-(2-oxopiperidin-1-yl)phenyl]-5,6-dihydro-1H-pyridin-2-one545445-44-1Apixaban intermediate
3-(4-Morpholinyl)-1-(4-nitrophenyl)-5,6-dihydro-2(1H)-pyridinone503615-03-0Apixaban intermediate
Ethyl 1-(4-methoxyphenyl)-6-(4-nitrophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3536759-91-8Apixaban intermediate
ethyl 6-(4-aMinophenyl)-1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate503615-07-4Apixaban intermediate
1-(4-AMinophenyl)-5,6-dihydro-3-(4-Morpholinyl)-2(1h)-pyridinone1267610-26-3Apixaban intermediate

Apixaban is an anticoagulant used to reduce the risk of stroke and systemic embolism in patients with non valvular atrial fibrillation. 

A key component in helping our customers be first to market is a responsive supply chain.
We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity.
A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Apixaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity.
Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin.
By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.

Advantages:

High Quality API Powder Apixaban Intermediate CAS 27143-07-3High Quality API Powder Apixaban Intermediate CAS 27143-07-3Certificates:

 

 
High Quality API Powder Apixaban Intermediate CAS 27143-07-3
High Quality API Powder Apixaban Intermediate CAS 27143-07-3

 

 

FAQ

High Quality API Powder Apixaban Intermediate CAS 27143-07-3

We are looking forward to your inquiry

 

Pharmaceutical Intermediate

PNEUTEC.IT, 2023